<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532425</url>
  </required_header>
  <id_info>
    <org_study_id>BFTAF vs Atripla</org_study_id>
    <nct_id>NCT03532425</nct_id>
  </id_info>
  <brief_title>B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults</brief_title>
  <official_title>Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate to Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Virologically Suppressed Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atripla (ATP: FTC/TDF/EFV) was the first single pill treatment for HIV and was the most
      prescribed first-line treatment from approximately 2008 to 2013 for people infected with HIV.
      However, ATP has not been recommended as a &quot;preferred&quot; treatment for HIV since 2015, due to
      there now being single pill treatments that work better. There are a lot of people who are
      still taking ATP and it is working for them. However, it has the potential to cause serious
      side effects (chronic kidney disease and fractures and serious neurological effects). These
      side effects are caused by components in ATP (namely the TDF and EFV parts). Also, the
      efavirenz (EFV) component is not compatible for treatment of Hepatitis C (HCV) - which is
      often also seen in people who have HIV. For these reasons, there is a need to find a better
      alternative treatment for these people currently being treated with ATP.

      B/F/TAF (bictegravir/FTC/TAF) is an investigational single pill drug treatment drug that
      contains neither TDF nor EFV. This study is looking at whether changing people to this new
      drug treatment will continue to suppress their HIV and have fewer side effects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urine albumin/creatinine ratio (UACR)</measure>
    <time_frame>baseline and week 48</time_frame>
    <description>change in urine albumin/creatinine ratio (UACR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA</measure>
    <time_frame>week 48</time_frame>
    <description>Number of participants with HIV-1 RNA &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efavirenz (EFV) symptom scores</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>change in EFV symptom scores from Pittsburgh Sleep Quality Questionnaire (PSQI) global score. PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. The PSQI global score has a possible range of 0-21. Higher scores represent worse sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine protein/creatinine ratio (UPCR)</measure>
    <time_frame>baseline and week 48</time_frame>
    <description>change in urine protein/creatinine ratio (UPCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>baseline and week 48</time_frame>
    <description>change in estimated glomerular filtration rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density (BMD) at the hip</measure>
    <time_frame>baseline and week 48</time_frame>
    <description>change in bone mineral density (BMD) at the hip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density (BMD) at the spine</measure>
    <time_frame>baseline and week 48</time_frame>
    <description>change in bone mineral density (BMD) at the spine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 lymphocyte counts</measure>
    <time_frame>baseline and week 48</time_frame>
    <description>change in CD4 lymphocyte counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>baseline and week 48</time_frame>
    <description>change in serum lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 36, and week 48</time_frame>
    <description>number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B/F/TAF + Atripla Placebo
Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atripla</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atripla + B/F/TAF Placebo
Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily</description>
    <arm_group_label>B/F/TAF</arm_group_label>
    <other_name>BIKTARVYÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atripla</intervention_name>
    <description>Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily</description>
    <arm_group_label>Atripla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF Placebo</intervention_name>
    <description>Tablet taken orally once daily</description>
    <arm_group_label>Atripla</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atripla Placebo</intervention_name>
    <description>Tablet taken orally once daily</description>
    <arm_group_label>B/F/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 seropositive

          2. Age &gt; 21 years

          3. Receiving ATP &gt; 2 years as their only ART, with HIV-1 RNA &lt; 50 copies/mL at screening
             and all HIV-1 RNA tests &lt; 100 copies/mL in the past 18 months

          4. No documented resistance mutations to the components of ATP

          5. Any CD4 count, but no active AIDS-defining opportunistic infections or cancers

          6. HBsAg+ permitted if plasma HBV DNA is unquantifiable and the patient does not have
             decompensated liver disease

          7. HCV RNA+ permitted if the patient has F0/1 hepatic fibrosis and anti-HCV therapy is
             not planned during the 52 weeks of blinded ART

        Exclusion Criteria:

          1. Pregnancy, breastfeeding or planned pregnancy in the next 2 years

          2. Documented resistance to the components of ATP

          3. Active AIDS-defining opportunistic infection or cancer

          4. Cancer in past 3 years, except non melanoma skin cancer

          5. Active psychotic disease or active depression that may interfere with study
             participation according investigator discretion

          6. Any illness with a life expectancy less than 2 years

          7. eGFR &lt; 50 mL/min

          8. Urine protein/creatinine &gt; 40 mg/mmoL

          9. Patients who the investigator feels are unlikely to commit to the study requirements
             for any reason

         10. Prescription drug therapy for osteoporosis (calcium and/or vitamin D is allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen D Shafran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen D Shafran, MD</last_name>
    <phone>780-407-6945</phone>
    <email>sshafran@ualberta.ca</email>
  </overall_contact>
  <link>
    <url>http://www.gilead.com/news/press-releases/2017/5/gileads-investigational-fixeddose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-the-treatment-of-hiv1-meets-primary-endpoint-in-four-phase-3-studies</url>
  </link>
  <reference>
    <citation>Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.</citation>
    <PMID>28867497</PMID>
  </reference>
  <reference>
    <citation>Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.</citation>
    <PMID>28867499</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

